Nexalin Technology, Inc. (NASDAQ:NXL) Sees 16.9% Drop in Short Interest
Nexalin Technology, Inc. (NASDAQ:NXL) experienced a significant decrease in short interest during the month of May. As of May 31st, the short interest totaled 60,600 shares, marking a 16.9% decline from the May 15th figure of 72,900 shares. Notably, approximately 1.0% of the company's shares are sold short. Given an average daily trading volume of 544,300 shares, the short-interest ratio currently stands at 0.1 days.
Nexalin Technology Price Performance
Nexalin Technology stock opened at $0.90 on Friday. Throughout the past year, the stock has seen a low of $0.25 and a high of $3.40. The stock boasts a market capitalization of $6.69 million, a PE ratio of -1.36, and a beta of 5.13. The business’s fifty-day moving average is $1.31, and its 200-day moving average is $0.80.
Recent Earnings Results
Nexalin Technology last reported its earnings on March 27th. The company announced ($0.10) earnings per share (EPS) for the quarter. The firm posted revenue of $0.02 million during this period. Investors noted the company's negative return on equity of 154.84% and a negative net margin of 3,088.12%.
Nexalin Technology Company Profile
Nexalin Technology, Inc., a medical device firm, is engaged in designing and developing neurostimulation products aimed at treating mental health conditions within the United States and China. The company is advancing its Generation 2 and Generation 3 products, currently in clinical trials for the treatment of substance abuse issues related to opiates, cocaine, and alcohol, as well as Alzheimer's disease and dementia.
For more detailed financial insights and stock performance, visit NASDAQ.
